Veterinary Biomarkers Market
Report ID: SQMIG35H2575
Report ID: SQMIG35H2575
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35H2575 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
155
|Figures:
78
Global Veterinary Biomarkers Market size was valued at USD 2.1 Billion in 2024 and is poised to grow from USD 2.35 Billion in 2025 to USD 5.77 Billion by 2033, growing at a CAGR of 11.88% during the forecast period (2026-2033).
High emphasis on early disease detection in animals, rising pet ownership, increasing demand for precision veterinary medicine, advancements in diagnostic technologies, and expanding focus on livestock health management are driving sales of veterinary biomarkers.
The growing need for accurate and early diagnosis of animal diseases is expected to primarily drive veterinary biomarkers market growth. Rising awareness of preventive animal health care and rising expenditure on companion animal care is expected to facilitate the adoption of biomarker-based diagnostic tools. The use of biomarkers for disease diagnostics, monitoring treatment efficacy and prognosis in companion animals as well as livestock is gaining popularity among veterinary practitioners. Advances in molecular diagnostics, multiplex testing platforms and point of care diagnostic devices are making the testing process quicker and more reliable, pushing veterinary biomarker-based diagnostics into the mainstream. Moreover, increasing investments in animal health research and enhanced acceptance of precision veterinary medicine among pet owners is likely to open up new avenues for veterinary biomarker providers soon.
However, high costs associated with advanced diagnostic testing, limited availability of validated biomarkers for certain conditions, regulatory challenges, and lack of awareness in developing regions are anticipated to slow down veterinary biomarkers market penetration across the forecast period.
How is AI Improving Diagnostic Accuracy of Veterinary Biomarkers?
AI is enhancing diagnosis in the veterinary markers market through a combination of sophisticated pattern recognition capabilities and analysis of more than one type of clinical information-whether it is biomarker pattern recognition or the integration of multiple information types-making medical image recognition and analysis and the recognition of multiple measurements of biomarker patterns easier and more reliable. AI is heavily innovating in point-of-care diagnostic platforms that help reduce interpretation variability with all newly introduced tests and help veterinarians achieve stable and practical clinical decision-making. With the increased drive for faster, more predictable testing, AI is making an increasing contribution at the point of care in the veterinary setting and in reference laboratories. Examples of these offerings are AI-enabled cytology and urine sediment analyzers that can distinguish abnormal cells and identify the high-priority or more risky samples to help guide lab and veterinarians' interpretation.
Market snapshot - (2026-2033)
Global Market Size
USD 2.1 Billion
Largest Segment
Physiological Biomarkers
Fastest Growth
Genetic Biomarkers
Growth Rate
11.88% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global veterinary biomarkers market is segmented by biomarker type, disease indication, animal type, application, end user, and region. Based on biomarker type, the market is segmented into genetic biomarkers, proteomic biomarkers, metabolomic biomarkers, imaging biomarkers, physiological biomarkers, and others. Based on disease indication, the market is segmented into infectious diseases, oncology, cardiovascular diseases, neurological disorders, metabolic disorders, autoimmune diseases, reproductive & fertility disorders, and others. Based on animal type, the market is segmented into companion animals, and livestock Animals. Based on application, the market is segmented into disease diagnosis, drug discovery & development, disease monitoring, personalized veterinary medicine, and research applications. Based on end user, the market is segmented into veterinary diagnostic laboratories, veterinary hospitals & clinics, research & academic institutes, pharmaceutical & biotechnology companies, and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The proteomic biomarkers segment is forecasted to account for the highest global veterinary biomarkers market share in the future. Proteomic assays, which identify and quantify functional proteins and posttranslational modifications, offer A direct method of examining disease processes and are critical to diagnosis and treatment decisions in the veterinary clinic. Proteomic testing is likely to be the dominant form of information for diagnosis and therapy due to the following reasons: advances in mass spectrometry and antibody technology; existing clinical pathways utilizing protein tests; widespread clinical value for a range of infectious, cancerous, and metabolic diseases; healthy diagnostic laboratory demand for desirable biomarkers; and potential for disease improvement.
However, genetic biomarkers are witnessing the strongest growth momentum while advancing disease risk profiling, breed specific diagnostics and pharmocatogenomic guided therapies in veterinary medicine. Growth will be driven by lower sequencing costs, expanding panels, integration into breeding and wellness programs and biotech company investment in targeted diagnostics and therapies.
The disease diagnosis segment is slated to lead the global veterinary biomarkers market revenue generation in the long run. Diagnostic biomarkers represent the central value proposition for veterinary testing. They are the foundation for enabling early diagnosis, differential diagnosis, and treatment decisions in all clinical settings. Diagnostic biomarkers lead the veterinary sector because of the routine nature of their clinical demand and concomitant sample collection workflows, insurers and client's willingness to pay for actionable information, established regulatory pathways for diagnostic assays, and their direct relation to improved clinical outcome which makes diagnostic readouts essential to the veterinarian and diagnostic laboratory alike.
Meanwhile, personalized veterinary medicine is the fastest growing application as per this veterinary biomarkers industry analysis, as multi marker panels and pharmacogenomics allow personalized medicines to be delivered, increased consumer interest in personalized veterinary care, new investment and interest from biotech and pharmaceutical companies investing in targeted medicines, and continued adoption of precision medicine technologies.
To get detailed segments analysis, Request a Free Sample Report
Advanced research infrastructure, strong private and public investment in animal health, and a sophisticated veterinary services network are helping this region hold sway over others. Increasing collaboration between academic institutions, contract research organizations, and industry participants driving biomarker discovery and validation at an accelerated pace. Additionally, there is a well-established regulatory framework and a sufficient number of existing diagnostic labs in place to allow for rapid adoption of new assays into clinical practice. Furthermore, the presence of a high concentration of biotechnology companies translates scientific discoveries into new commercial products, while the existence of well-integrated supply chains enables veterinary biomarkers to be distributed throughout both the companion animal and agricultural segments of the marketplace. In conclusion, scientific capability, regulatory clarity, and overall market readiness contribute to North America's continued leadership position in veterinary biomarkers and its ability to influence global standards and best practices.
Demand for veterinary biomarkers in United States benefits from research centers and biotech firms that drive diagnostic innovation. Clinical adoption is supported by specialized veterinary hospitals and a regulatory environment encouraging rigorous validation. Collaboration between industry and academia fosters pipeline development while established reagent and device manufacturers ensure supply and commercialization. The market balances advanced diagnostics for companion animal care with practical solutions for livestock productivity and farm health needs effectively.
Veterinary biomarker adoption in Canada benefits from collaborative research networks and a veterinary services base oriented toward companion animals and production livestock. A focus on research and forging collaborations with biotech suppliers is progress that will advance assay development and localized validation. The industry itself will promote uptake by developing laboratory solutions and diagnostic products specific to the local target population disease spectrum. The market benefits from the development of capacity and a practical approach to the routine implementation of biomarkers in veterinary medicine.
Strong research capabilities, harmonized regulatory initiatives, and a growing emphasis on precision veterinary medicine across clinical and agricultural sectors are helping create new opportunities. Key players in the market have formed collaborative consortia to facilitate the qualification of biomarkers, leading to greater acceptance of these new technologies in clinical settings through cross-border validation processes. In addition, rising demand for disease monitoring and control of antimicrobial use, as well as the humane treatment of animals, provides motivation for the development of new assays using targeted approaches. Furthermore, the presence of an established infrastructure for diagnostic services along with increased investments by biotechnology companies will help to facilitate the commercialization of new diagnostics. The integration of public health and surveillance initiatives into the existing veterinary community creates a demand for standardized biomarkers that will provide information on how to manage zoonotic (animal-to-human) disease risk. Similarly, companies with existing diagnostic services will leverage their regional harmonization to maximize demand across European countries.
Sales of veterinary biomarkers in Germany are anchored by an industrial biotech sector and veterinary research institutions focused on diagnostic validation and translational science. Collaboration between universities, research agencies, and private laboratories enables rigorous assay development and standardization. Clinical veterinary networks and diagnostic service providers support uptake in companion and production animal settings. The market benefits from a manufacturing base and an ecosystem oriented toward quality, regulatory compliance, and innovation.
Demand for veterinary biomarkers in United Kingdom is characterized by a vibrant startup community and translational research hubs that accelerate commercialization of novel assays. Flexible funding streams and industry evaluation push for the adoption in clinical practice and surveillance programs. Good links between universities, Vets clinics and diagnostics companies push for quick validation. The market proves to be flexible for digital tools and lab networks for targeted diagnostics for companion and production animal.
Veterinary biomarkers market in France is emerging through public research institutes and growing collaboration with diagnostics companies focused on regional disease challenges. Focus on animal welfare and food security amidst modern global challenges increases interest in validated animal health biomarkers for monitoring and herd health management. Market, research and operational cooperation emerges at levels of clinical laboratory and veterinary collaboration to facilitate piloting, while incubators and initiatives foster initial technologies. The market trend is eventually directed toward standardization and real word utility.
Concentrated investments in life science infrastructure, a maturing biotechnology industry, and increasing integration of diagnostics into animal health programs are creating an opportune setting in the region. Investigators working out of regional research laboratories and private companies are developing biomarker platforms that support local disease populations, production systems, and animal breeds, while global collaborators accelerate knowledge transfer and dissemination. Additional veterinary clinical capacity and laboratory networks further strengthen ability to validate and ship products. Policy initiatives that provide emphasis on food safety and zoonotic diseases generate market demand for consistent biomarker solutions. Developed digital diagnostics combined with point of care technology will enhance laboratory capacity along with decision-making support for practitioners and producers in the field. Strengthened veterinary training and collaboration between the public and private sectors are leading to the continued acceptance of biomarkers as part of routine health care and surveillance.
Demand for veterinary biomarkers in Japan benefits from advanced biomedical and industrial research focused on assay refinement and quality standards. Partnerships between universities, external corporate labs and clinical veterinary networks underpayment validation and implementation for companion and production animal care. Focus on precision diagnosis and connection to digital health stakeholders enabled integration with point of care solutions. Includes regulatory pathways and manufacturing proficiency to allow successful transition of research developments into diagnostic products across the field.
Veterinary biomarkers market in South Korea is advancing through coordinated public private initiatives and strong electronics expertise that supports biosensor development and point of care platforms. Research organizations work closely with veterinary clinics to validate biomarkers in production systems and companion animal health. A manufacturing ecosystem equipped for components enables local manufacture of assay devices. The target market shows a pragmatic approach to commercialization, focused on technology integration and industry partnership.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Companion Animal Healthcare Investment
Advances In Molecular Diagnostics
Regulatory Hurdles For Diagnostic Approval
Limited Standardization and Reimbursement
Request Free Customization of this report to help us to meet your business objectives.
Competition in the veterinary biomarkers market is driven by incumbents expanding assay menus and executing acquisitions while specialist startups introduce disruptive tests and AI platforms. Large diagnostics firms are launching new biomarker assays and acquiring point of care technologies, exemplified by IDEXX expanding cancer and kidney biomarker offerings and Zomedica acquiring point of care diagnostic platforms. Startups force faster validation and partnership activity through microRNA and urine based screening innovations.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, high emphasis on early disease detection in animals, rising pet ownership, and increasing adoption of precision veterinary medicine are anticipated to drive the demand for veterinary biomarkers going forward. However, high costs of advanced diagnostic testing and limited availability of validated biomarkers for certain conditions are slated to slow down the adoption of veterinary biomarkers in the future. North America is slated to spearhead the demand for veterinary biomarkers owing to high spending on animal healthcare, advanced veterinary diagnostic infrastructure, and strong presence of leading animal health companies. AI-powered diagnostic interpretation tools and the integration of biomarker testing with point-of-care diagnostic platforms are anticipated to be key trends driving the veterinary biomarkers industry through 2033.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 2.1 Billion |
| Market size value in 2033 | USD 5.77 Billion |
| Growth Rate | 11.88% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Veterinary Biomarkers Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Veterinary Biomarkers Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Veterinary Biomarkers Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Veterinary Biomarkers Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Veterinary Biomarkers Market size was valued at USD 2.1 Billion in 2024 and is poised to grow from USD 2.35 Billion in 2025 to USD 5.77 Billion by 2033, growing at a CAGR of 11.88% during the forecast period (2026-2033).
Competition in the veterinary biomarkers market is driven by incumbents expanding assay menus and executing acquisitions while specialist startups introduce disruptive tests and AI platforms. Large diagnostics firms are launching new biomarker assays and acquiring point of care technologies, exemplified by IDEXX expanding cancer and kidney biomarker offerings and Zomedica acquiring point of care diagnostic platforms. Startups force faster validation and partnership activity through microRNA and urine based screening innovations. 'Zoetis Inc.', 'IDEXX Laboratories, Inc.', 'Thermo Fisher Scientific Inc.', 'Merck & Co., Inc.', 'Elanco Animal Health Incorporated', 'Virbac', 'Heska Corporation', 'Neogen Corporation', 'Randox Laboratories Ltd.', 'Bio-Rad Laboratories, Inc.', 'QIAGEN N.V.', 'Agilent Technologies, Inc.', 'PerkinElmer Inc.', 'Abcam plc', 'Biomérieux SA', 'Eurofins Scientific', 'Creative Diagnostics', 'Avacta Group plc', 'AniCura', 'Mars Incorporated'
Investment in companion animal healthcare has led to expanded research funding, advanced diagnostic development, and increased commercial interest in veterinary biomarkers. Pharmaceutical and diagnostics companies channel resources into biomarker discovery and validation, enabling the translation of laboratory findings into marketable assays. Veterinary clinics adopt newer diagnostic platforms as industry support lowers costs and improves availability, which in turn broadens clinician acceptance. This cycle of investment, product development, and clinical uptake strengthens the value proposition for biomarkers, encouraging further private and institutional funding and fostering sustained market growth.
Personalized Veterinary Medicine: Demand for individualized treatment pathways is driving interest in biomarkers that support tailored diagnostics, prognosis, and therapeutic selection for companion and production animals. Stakeholders emphasize translational research linking genomic, proteomic, and metabolic indicators to clinical decision frameworks, enabling earlier intervention and improved welfare outcomes. Veterinary practitioners seek tools that integrate into clinical workflows and provide actionable insights. Strategic partnerships between diagnostics developers, academic centers, and veterinary networks accelerate validation and uptake, positioning personalized approaches as competitive differentiators for market adoption.
Why does North America Dominate the Global Veterinary Biomarkers Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
